← Full peptide calculator

Free tool

PT-141 (Bremelanotide) Dosage Calculator: mg to U-100 Units for On-Demand SC Doses

PT-141 (Bremelanotide) Dosage Calculator: mg to U-100 Units for On-Demand SC Doses

To convert PT-141 — also written PT 141 or bremelanotide — to syringe units, divide your dose in milligrams by the vial’s concentration (mg/mL), then multiply by 100 for a U-100 insulin syringe. Example: a 10 mg vial in 2 mL BAC water is 5 mg/mL, so 1.75 mg (the FDA-labeled amount) draws 35 units. Arithmetic only — not medical advice; verify with a licensed clinician.

PT-141 (Bremelanotide) reconstitution & dosage calculator X

Reconstitution / draw volume / syringe units / supply-chain

Arithmetic + reference toolNot medical advice
Inputs
Approved label
Product form
Target dose
Weight unit
Syringe barrel
Draw to
50units
0.5 mL5 mg/mL2.5 mg / dose
1 mL syringe - 100 u/mLFits
50 u050100 u
ARITHMETIC OK - VERIFY CLINICALLY

Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.

10 mg
4
0 mg
28 days
-
-

Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.

Reference context
Approved label
PT-141 (bremelanotide)
StatusFDA-approved as Vyleesi for a narrow labeled indicationRouteSubcutaneousFrequencyAs needed

1.75 mg at least 45 min before anticipated sexual activity; max 1 dose/24 h and not more than 8/month

Published range1.75 mg

Commercial Vyleesi is a 1.75 mg/0.3 mL autoinjector; no reconstitution required.

Contraindicated in uncontrolled hypertension or known cardiovascular disease.

FDA prescribing information (PT-141 (bremelanotide)) - accessdata.fda.gov
Finnrick supply-chain
Mar 2025 - Apr 2026
7/10
Avg quality score
27 vendors - 97 samples tested
96.09-99.95%
+/- 51 %
10 mg

Supply-chain signal only - not a potency guarantee. Enter the COA's tested mg and purity above so the math reflects the real vial.

View on finnrick.com
Reconstitution planner

Reverse: pick a dose and the units you want it to read, then calculate diluent to add.

Reverse
Desired dose
1 mL
10 mg/mL
4
Blend planner

Same-syringe co-draw. Reconstitute each peptide in its own vial, then draw them into one syringe.

Co-draw
2.5 mg/mLDraw 4 u · 0.04 mL
2.5 mg/mLDraw 4 u · 0.04 mL
Combined draw
Fits 1 mL8 u0.08 mL
  • Reconstitute each peptide in its own vial — never add water to multiple peptides in one vial.
  • Only co-draw peptides with the same diluent (e.g. both bacteriostatic water) and compatible pH.
  • Draw and inject fresh — do not pre-mix and store; mixture stability is not established.
  • No blended stack is clinically validated. Verify each component and confirm with a clinician.
Formula and source context only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol. Do not use this tool to infer sterility, potency, purity, stability, compatibility, or an appropriate dose. Catalog and supply-chain data: finnrick.com/products - research date 2026-06-24.

PT-141 (bremelanotide) dose to syringe units: reference chart

PT-141 (bremelanotide) - U-100 syringe units by vial size, water volume and dose
Vial + waterConcentrationUnits per 1 mg1.75 mg
10 mg + 1 mL10 mg/mL1017.5
10 mg + 2 mL5 mg/mL2035
10 mg + 3 mL3.33 mg/mL3052.5

Concentration = vial strength divided by the bacteriostatic water added. On a U-100 syringe 100 units = 1 mL, so units = (dose divided by concentration) x 100. Values are syringe units, not milligrams. Amber values exceed 100 units, which is more than one standard 1 mL U-100 syringe holds, so that combination needs a more concentrated solution. Columns are the dose steps named on the current FDA label - they describe what has been studied or labeled, not what anyone should take, and this page gives no dosing advice. Multiply the units-per-1-mg figure by your own dose in milligrams to convert any amount. For vial sizes or doses not shown here, use the general mg to units converter.

Sources

Frequently asked questions

Which condition is the FDA-approved form of bremelanotide indicated for?

Bremelanotide is sold as Vyleesi, approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA label 210557). That is a narrow, on-demand indication rather than a daily or general-purpose therapy.

Is bremelanotide taken on a fixed weekly schedule like some peptides?

No. Vyleesi is used on demand: one 1.75 mg subcutaneous dose at least 45 minutes before anticipated activity, with the label limiting use to one dose per 24 hours and no more than eight doses per month. This calculator only converts a milligram amount you enter, so it does not plan a schedule.

How does this tool work with a 10 mg research vial of PT-141?

Research-grade PT-141 usually comes as a lyophilized 10 mg vial that you reconstitute before measuring. After you enter the resulting concentration in mg per mL, the calculator converts your target milligram amount into U-100 insulin-syringe units. To decide how much bacteriostatic water to add first, use the /tools/bac-water-calculator.

Do I need to run the branded Vyleesi autoinjector through this calculator?

No. Vyleesi is supplied as a single-use 1.75 mg per 0.3 mL prefilled autoinjector, so there is nothing to mix or convert and it is used exactly as delivered. This tool applies only to loose research vials that you reconstitute yourself.

Does the Vyleesi label flag any cardiovascular cautions for bremelanotide?

Yes. The label lists contraindications for people with uncontrolled hypertension or known cardiovascular disease. This is a factual label note, and whether bremelanotide is appropriate for a given person is a determination for a licensed clinician.